The International Society for Neuroimmunology White Paper Task Force has presented comprehensive guidance reviewing the application of animal models in central nervous system neuroimmunology. Writing in Nature Reviews Neurology, the international task force evaluated how laboratory animal models serve as essential tools for capturing specific facets of human neurological disease, investigating underlying disease mechanisms, and identifying novel therapeutic targets and strategies across the preclinical research landscape.
Although studies using animal models have historically fuelled numerous breakthroughs in the rapidly expanding discipline of neuroimmunology, the authors emphasize that the broader literature has not adequately documented the extensive variety of available models alongside their relative merits and drawbacks. This lack of centralized and detailed documentation has created substantial hurdles for investigators venturing into neuroimmunological investigations, complicating model selection and baseline experimental design.
The task force highlights that subtle nuances between distinct animal models, their specific utility for modeling neuroimmunological processes, and diverse intrinsic and extrinsic variables can profoundly influence clinical and pathological readouts. When left uncharacterized or uncontrolled, these variables jeopardize both the experimental reproducibility and the ultimate clinical relevance of discoveries generated during early preclinical testing.
To address these challenges, the guidance outlines actionable frameworks for identifying and managing both intrinsic and extrinsic factors that shape experimental outcomes. The authors explain that systematically manipulating these variables allows researchers to gain critical insights into how specific biological influences govern neuroimmunological processes, whereas rigorously controlling them prevents artifacts and confounding factors to ensure dependable biological interpretations.
In addition to model selection and variable control, the review assesses the distinct advantages and current limitations of key experimental tools used across neuroimmunological investigations. The task force specifically examines the deployment of robust genetic systems, advanced neuroimmunological imaging modalities, functional physiological readouts, and omics-based single-cell and molecular profiling platforms designed to dissect complex cellular phenotypes.
Finally, the authors discuss how principles established in animal models have successfully driven drug development for neuroimmunological conditions, noting that these foundational methodologies provide broader insights applicable across diverse neurological disorders. Emphasizing the support of the preclinical drug discovery pipeline, the task force concludes that the continued evolution of scientific tools and experimental approaches will progressively refine animal models and enhance their power to uncover mechanisms vital to central nervous system health.
In addressing the documentation deficit within central nervous system neuroimmunology, the task force guidance emphasizes that researchers entering this expanding field face substantial hurdles due to the lack of centralized literature outlining the relative merits and drawbacks across existing animal models. Because preclinical breakthroughs in understanding human neurological disease depend heavily on these model systems, establishing clear documentation regarding model selection is critical for early experimental design. The guidance therefore systematically catalogs how different animal model systems capture specific aspects of human neurological disease, providing a foundational baseline for investigators seeking to match appropriate experimental systems to precise neuroimmunological research questions.
A central focus of the white paper involves the precise management of intrinsic and extrinsic variables that govern experimental readouts. The task force establishes a dual framework for handling these variables: on one hand, investigators are guided to intentionally manipulate intrinsic and extrinsic factors to uncover how distinct biological influences modulate neuroimmunological processes; on the other hand, the guidance directs researchers to stringently control these same variables during routine testing. By implementing rigorous experimental controls, laboratories can effectively prevent confounders and eliminate technical artifacts, ensuring that clinical and pathological observations accurately reflect genuine biological mechanisms rather than uncharacterized experimental variance.
The guidance further examines the specific experimental methodologies and technological platforms currently deployed across neuroimmunological investigations, assessing both their relative advantages and their operational limitations. The task force evaluates robust genetic systems alongside advanced neuroimmunological imaging modalities, functional physiological readouts, and omics-based cell profiling technologies. By weighing the analytical strengths and constraints of each technological approach, the task force provides researchers with practical strategies to interrogate cellular phenotypes and pathological outcomes without introducing confounding technical biases into preclinical evaluations.
To bridge laboratory findings with translational applications, the task force details how animal models have historically advanced drug development for neuroimmunological diseases and outlines methodologies to optimize their utility within the preclinical drug discovery pipeline. The authors emphasize that uncontrolled nuances between animal models and uncharacterized shifts in clinical or pathological readouts directly impair the reproducibility and clinical relevance of preclinical discoveries. Applying standardized principles of variable control and model optimization not only safeguards therapeutic target validation for neuroimmunological disorders but also offers a transferable framework that provides insight into a wide variety of broader central nervous system conditions.
Looking toward future directions in preclinical research, the white paper concludes that the continued evolution of scientific tools and experimental approaches will progressively refine animal model systems. As these methodological tools advance, their increasing analytical power will enhance the capacity of investigators to uncover complex neuroimmunological processes directly relevant to central nervous system health, thereby strengthening the evidentiary foundation required to identify new therapeutic targets and effective intervention strategies.
Subject of Research: Preclinical animal models and experimental standardization in central nervous system neuroimmunology
Article Title: Use of animal models to understand CNS neuroimmunology — guidance from the International Society for Neuroimmunology White Paper Task Force
Article References: Gommerman, J. L., Akassoglou, K., Baranzini, S. E., Becher, B., Brilot, F., Castelo-Branco, G., Dunn, S. E., Faiz, M., Flügel, A., Ghasemlou, N., Gibson, E. M., Greer, J. M., Gris, D., Harrington, C. A., Jung, S., Kalia, L. V., Korn, T., Krishnamoorthy, G., Liblau, R. S., … Miron, V. E. (2026). Use of animal models to understand CNS neuroimmunology — guidance from the International Society for Neuroimmunology White Paper Task Force. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01272-1
Image Credits: AI Generated
DOI: 10.1038/s41582-026-01272-1
Keywords: neuroimmunology, animal models, central nervous system, preclinical research, reproducibility, International Society for Neuroimmunology, drug discovery, genetic systems, neuroimmunological imaging, functional readouts, omics-based cell profiling, experimental variables, therapeutic targets, neurological disease, preclinical drug development, biological confounders, CNS pathology
News Source: Ophelia Keating. (November 16, 2026). Task Force Issues Guidance on Animal Models for CNS Neuroimmunology Research. Scienmag.



